Latest medical treatment strategies for venous thromboembolism

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 9, 2007, Pages 1221-1233

  McRae, Simon J ^a   Eikelboom, John W ^b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulant; Factor Xa inhibitor; Thrombin inhibitor; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; ANTIVITAMIN K; APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A; BMS 562247; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; IDRAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; PROTHROMBIN; RAZAXABAN; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; RIVAROXABAN; THROMBIN INHIBITOR; TINZAPARIN; TTP 889; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; AREA UNDER THE CURVE; BLEEDING; BLEEDING DISORDER; BLOOD CLOTTING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DEATH; DEEP VEIN THROMBOSIS; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSTEOPOROSIS; POSTTHROMBOSIS SYNDROME; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM; PATHOPHYSIOLOGY; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION; HUMANS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 34250901454     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.9.1221     Document Type: Review

References (94)

1. BARRITT DW, JORDAN SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet (1960) 1:1309-1312.
2. LAGERSTEDT CI, OLSSON CG, FAGHER BO, OQYIST BW, ALBRECHTSSON U: Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet (1985) 2(8454):515-518.
3. HULL RD, RASKOB GE, HIRSH J et al.: Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N. Engl. J. Med. (1986) 315(18): 1109-1114.
4. HIRSH J, RASCHKE R: Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(3 Suppl.):188S-203S.
5. ANSELL J, HIRSH J, POLLER L, BUSSEY H, JACOBSON A, HYLEK E: The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 126(3 Suppl.):204S-233S.
6. VAN DONGEN CJ, VAN DEN BELT AG, PRINS MH, LENSING AW: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst. Rev. (2004) 4:CD01100.
7. LINICINS LA, CHOI PT, DOUKETIS JD: Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann. Intern. Med. (2003) 139(11):893-900.
8. PALARETI G, LEALI N, COCCHERI S et al.: Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet (1996) 348(9025):423-428.
9. HIRSH J, O'DONNELL M, WEITZ JI: New anticoagulants. Blood (2005) 105(2):453-463.
10. BATES SM, WEITZ JI: The status of new anticoagulants. Br. J. Haematol. (2006) 134(1):3-19.
11. KAUL S, DIAMOND GA: Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann. Intern. Med. (2006) 145(1):62-69.
12. DAVIE EW: Biochemical and molecular aspects of the coagulation cascade. Thromb. Haemost. (1995) 74(1):1-6.
13. MANN KG: Thrombin formation. Chest (2003) 124(3 Suppl.):4S-10S.
14. BAUGH RJ, BROZE GJ, Jr:, KRISHNASWAMY S: Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor. J. Biol. Chem. (1998) 273(8):4378-4386.
15. ESMON CT: The roles of protein C and thrombomodulin in the regulation of blood coagulation. J. Biol. Chem. (1989) 264(9):4743-4746.
16. QUINLAN DJ, MCQUILLAN A, EIKELBOOM JW: Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann. Intern. Med. (2004) 140(3):175-183.
17. MISMETTI P, QUENET S, LEVINE M et al.: Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis. Chest (2005) 128(4):2203-2210.
18. VAN DONGEN CJ, MAC GILLAVRY MR, PRINS MH: Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst. Rev. (2003) 1:CD003074.
19. ZIDANE M, VAN HULSTEIJN LH, BRENNINKMEIJER BJ, HUISMAN MV: Out of hospital treatment with subcutaneous low molecular weight heparin in patients with acute deep-vein thrombosis: a prospective study in daily practice. Haematologica (2006) 91(8):1052-1058.
20. DAGER WE, KING JH, BRANCH JM et al.: Tirizaparin in outpatients with pulmonary embolism or deep vein thrombosis. Ann. Pharmacother. (2005) 39(7-8):1182-1187.
21. AGNELLI G, PRANDONI P, SANTAMARIA MG et al.: Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N. Engl. J. Med. (2001) 345(3):165-169.
22. WELLS PS, ANDERSON DR, RODGER MA et al.: A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch. Intern. Med. (2005) 165(7):733-738.
23. LEE AY, LEVINE MN, BAKER RI et al.: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. (2003) 349(2):146-153.
24. WEITZ JI: Low-molecular-weight heparins. N. Engl. J. Med. (1997) 337(10):688-698.
25. DOLOVICH LR, GINSBERG JS, DOUKETIS JD, HOLBROOK AM, CHEAH G: A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch. Intern. Med. (2000) 160(2):181-188.
26. AL-YASEEN E, WELLS PS, ANDERSON J, MARTIN J, KOVACS MJ: The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J. Thromb. Haemost. (2005) 3(1):100-102.
27. BARBA R, MARCO J, MARTIN-ALVAREZ H et al.: The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J. Thromb. Haemost. (2005) 3(5):856-862.
28. IORIO A, GUERCINI F, PINI M: Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J. Thromb. Haemost. (2003) 1(9):1906-1913.
29. DASKALOPOULOS ME, DASKALOPOULOU SS, TZORTZIS E et al.: Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur. J. Vasc. Endovasc. Surg. (2005) 29(6):638-650.
30. BECKMAN JA, DUNN K, SASAHARA AA, GOLDHABER SZ: Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thromb. Haemost. (2003) 89(6):953-958.
31. PRANDONI P, LENSING AW, PICCIOLI A et al.: Recurrent venous thromboembolism, and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 100(10):3484-3488.
32. MEYER G, MARJANOVIC Z, VALCKE J et al.: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch. Intern. Med. (2002) 162(15):1729-1735.
33. BULLER HR, AGNELLI G, HULL RD, HYERS TM, PRINS MH, RASKOB GE: Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and ThrombolyticTherapy. Chest (2004) 126(3 Suppl.):401S-428S.
34. MCRAE SJ, GINSBERG JS: Initial treatment of venous thromboembolism. Circulation (2004) 110(9 Suppl. 1):I3-I9.
35. PRANDONI P, CARNOVALI M, MARCHIORI A: Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch. Intern. Med. (2004) 164(10):1077-1083.
36. KEARON C, GINSBERG JS, JULIAN JA et al.: Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA (2006) 296(8):935-942.
37. CARSON JL: Subcutaneous unfractionated heparin vs low-molecular-weight heparin for acute thromboembolic disease: issues of efficacy and cost. JAMA (2006) 296(8):991-993.
38. PRANDONI P, SIRAGUSA S, GIROLAMI B, FABRIS F: The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood (2005) 106(9):3049-3054.
39. MARTEL N, LEE J, WELLS PS: Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood (2005) 106(8):2710-2715.
40. LEE AY, VLASUK GP: Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation Factor VIIa/tissue factor. J. Intern. Med. (2003) 254(4):313-321.
41. BERGUM PW, CRUIKSHANK A, MAKI SI, KELLY CR, RUF W, VLASUK GP: Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2. J. Biol. Chem. (2001) 276(13):10063-10071.
42. VLASUK GP, BRADBURY A, LOPEZ-KINNINGER L et al.: Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man. Dependence on the stoichiometric binding to circulating factor X. Thromb. Haemost. (2003) 90(5):803-812.
43. LEE A, AGNELLI G, BULLER H et al.: Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembotism in patients undergoing total knee replacement. Circulation (2001) 104(1):74-78.
44. BULLER HR: Factor Xa is a superior target to factor IIa for antithrombotic therapies. Semin. Thromb. Hemost. (2003) 29(Suppl, 1):37.
45. CHOAY J, LORMEAU JC, PETITOU M, SINAY P, FAREED J: Structural studies on a biologically active hexasaccharide obtained from heparin. Ann. N Y Acad. Sci. (1981) 370:644-649.
46. OLSON ST, BJORK I, SHEFFER R, CRAIG PA, SHORE JD, CHOAY J: Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J. Biol. Chem. (1992) 267(18):12528-38.
47. OLSON ST, SWANSON R, RAUB-SEGALL E et al.: Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb. Haemost. (2004) 92(5):929-939.
48. PETROS S, SIEGEMUND T, SIEGEMUND A, ENGELMANN L: The effect of different anticoagulants on thrombin generation. Blood Coagul. Fibrinolysis (2006) 17(2):131-137.
49. GEROTZIAFAS GT, DEPASSE F, CHAKROUN T, VAN DREDEN P, SAMAMA MM, ELALAMY I: Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in vitro dotting of whole blood and platelet-rich plasma. Blood Coagul. Fibrinolysis (2004) 15(2):149-156.
50. BRUFATTO N, WARD A, NESHEIM ME: Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J. Thromb. Haemost. (2003) 1(6):1258-1263.
51. DONAT F, DURET JP, SANTONI A et al.: The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin. Pharmacokinet. (2002) 41(Suppl. 2):1-9.
52. BONEU B, NECCIARI J, CARIOU R et al.: Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb. Haemost. (1995) 74(6):1468-1473.
53. BULLER HR, DAVIDSON BL, DECOUSUS H et al.: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann. Intern. Med. (2004) 140(11):867-873.
54. BULLER HR, DAVIDSON BL, DECOUSUS H et al.: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N. Engl. J. Med. (2003) 349(18):1695-702.
55. SAVI P, CHONG BH, GREINACHER A et al.: Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood (2005) 105(1):39-144.
56. GREINACHER A, GOPINADHAN M, GUNTHER JU et al.: Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler. Thromb. Vasc. Biol. (2006) 26(10):2386-2393.
57. KOVACS MJ: Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb. Haemost. (2005) 93(5):999-1000.
58. HARENBERG J, JORG I, FENYVESI T: Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica (2004) 89(8):1017-1018.
59. HERBERT JM, HERAULT JP, BERNAT A et al.: Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood (1998) 91(11):4197-205.
60. THE PERSIST INVESTIGATORS: A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation. J. Thromb. Haemost. (2004) 2(1):47-53.
61. BIJSTERVELD NR, VINK R, VAN AKEN BE et al.: Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br. J. Haematol. (2004) 124(5):653-658.
62. DA0 A, TUAN B, CARLSON N: Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa. Am. J. Med. (2005) 118(10):1172-1173.
63. PERZBORN E, STRASSBURGER J, WILMEN A et al.: In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J. Thromb. Haemost. (2005) 3(3):514-521.
64. KUBITZA D, BECKA M, VOITH B, ZUEHLSDORF M, WENSING G: Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. (2005) 78(4):412-421.
65. ERIKSSON BI, BORRIS L, DAHL OE et al.: Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J. Thromb. Haemost. (2006) 4(1):121-128.
66. TURPIE AG, FISHER WD, BAUER KA et al.: BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J. Thromb. Haemost. (2005) 3(11):2479-2486.
67. AGNELLI G, GALLUS A, GOLDHABER SZ et al.: Treatment of acute, symptomatic, proximal deep vein thrombosis with the oral, direct, Factor Xa inhibitor rivaroxaban (BAY 59-7939) - the ODIXa-DVT dose-ranging study. Eur. Heart J. (2006) 27(Suppl.):761 (Abstr. P4569).
68. BULLER HR: Once-daily treatment with oral, direct FActor Xa inhibitor-Rivoroxaban (BAY 59-7939) - in patients with acute, symptomatic deep vein thrombosis. The EINSTEIN-DVT dose-finding study. Eur. Heart J. (2006) 27(suppl):761 (Abstr. 89702).
69. ERIKSSON BI, QUINLAN DJ: Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs (2006) 66(11):1411-1429.
70. TURPIE AG: Oral direct factor Xa Inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. (2007) [Epub ahead of print].
71. LASSEN MR, DAVIDSON BL, GALLUS A, PINED G, ANSELL J, DEITCHMAN D: A Phase II randomized, double-blind, eight-arm, parallel-group, dose-response study of apixaban, a new oral factor Xa inhibitor for the prevention of deep vein thrombosisin knee replacement surgery - on behalf of the Apixaban Investigators. Blood (2006) 108(11, November 16):Abstr. 574.
72. WEITZ JI, CROWTHER M: Direct thrombin inhibitors. Thromb. Res. (2002) 106(3):V275-V284.
73. DI NISIO M, MIDDELDORP S, BULLER HR: Direct thrombin inhibitors. N. Engl. J. Med. (2005) 353(10):1028-1040.
74. KEELING D, DAVIDSON S, WATSON H: The management of heparin-induced thrombocytopenia. Br. J. Haematol. (2006) 133(3):259-269.
75. GUSTAFSSON D: Oral direct thrombin inhibitors in clinical development. J. Intern. Med. (2003) 254(4):322-334.
76. SCHULMAN S, WAHLANDER K, LUNDSTROM T, CLASON SB, ERIKSSON H: Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N. Engl. J. Med. (2003) 349(18):1713-1721.
77. Is that it, then, for blockbuster drugs? Lancet (2004) 364(9440):1100.
78. OLSSON SB: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet (2003) 362(9397):1691-1698.
79. ERIKSSON BI, DAHL OE, BULLER HR et al.: A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost. (2005) 3(1):103-111.
80. DITTMAN WA, MAJERUS PW: Structure and function of thrombomodulin: a natural anticoagulant. Blood (1990) 75(2):329-336.
81. KEARON C, COMP C, DOUKETIS J, ROYDS R, YAMADA K, GENT M: A dose-response study of a recombinant human soluble thrombomodulin (ART-123) for prevention of venous thromboembolism after unilateral total hip replacemcnt. J. Thromb. Haemost. (2003) 1(Suppl. 1):Abstr. OC330.
82. PRANDONI P, LENSING AW, COGO A et al.: The long-term clinical course of acute deep venous thrombosis. Ann. Intern. Med. (1996) 125(1):1-7.
83. WELLS PS, FORSTER AJ: Thrombolysis in deep vein thrombosis: is there still an indication? Thromb. Haemost. (2001) 86(1):499-508.
84. WAN S, QUINLAN DJ, AGNELLI G, EIKELBOOM JW: Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation (2004) 110(6):744-749.
85. JERJES-SANCHEZ C, RAMIREZ-RIVERA A, DE LOURDES GARCIA M et al.: Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J. Thromb. Thrombolysis (1995) 2(3):227-229.
86. KONSTANTINIDES S, GEIBEL A, HEUSEL G, HEINRICH F, KASPER W: Heparin plus alteplase compared with heparin alone in patients with submassive puhnonary embolism. N. Engl. J. Med. (2002) 347(15):1143-1150.
87. ARCELUS JI, CAPRINI JA, MONREAL M, SUAREZ C, GONZALEZ-FAJARDO J: The management and outcome of acute venous thromboembolism: a prospective registry including 4011 patients. J. Vasc. Surg. (2003) 38(5):916-922.
88. TRUJILLO-SANTOS J, PEREA-MILLA E, JIMENEZ-PUENTE A et al.: Bed rest or ambulation in the initial treatment of patients with acute deep vein thrombosis or pulmonary embolism: findings from the RIETE registry. Chest (2005) 127(5):1631-1636.
89. SCHELLONG SM, SCHWARZ T, KROPP J, PRESCHER Y, BEUTHIEN-BAUMANN B, DANIEL WG: Bed rest in deep vein thrombosis and the incidence of scintigraphic pulmonary embolism. Thromb. Haemost. (1999) 82(Suppl. 1):127-129.
90. ASCHWANDEN M, LABS KH, ENGEL H et al.: Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism. Thromb. Haemost. (2001) 85(1):42-46.
91. PARTSCH H, BLATTLER W: Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J. Vasc. Surg. (2000) 32(5):861-869.
92. KAHN SR: The post-thrombotic syndrome: progress and pitfalls. Br. J. Haematol. (2006) 134(4):357-365.
93. PRANDONI P, LENSING AW, PRINS MH et al.: Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann. Intern. Med. (2004) 141(4):249-256.
94. KAKKOS SK, DASKALOPOULOU SS, DASKALOPOULOS ME, NICOLAIDES AN, GEROULAKOS G: Review on the value of graduated elastic compression stockings after deep vein thrombosis. Thromb. Haemost. (2006) 96(4):441-445.